

Anti-Cancer Drugs 2009

Keyword Index to Volume 20

- 5-fluorouracil, 165, 281, 668, 822, 845, 941
5-fluorouracil insulin-like growth factor-binding protein-3, 21
78-kDa glucose-regulatory protein, 601
ABT-751, 483
accumulation in mitochondria, 461
acquired resistance, 321
activated hemicellulose compound, 215
activity and toxicity, 277
acute myeloid leukemia, 7, 693
adenocarcinoma of the esophago-gastric junction, 75
adenosine 5'-triphosphate, 625
adjuvant chemotherapy, 503
adriamycin, 800
adriamycin (doxorubicin), 779
advanced disease, 409
advanced gastric cancer, 191, 281, 287, 941
adverse effects, 157
aflibercept, 81
Akt, 59, 259, 444
all-*trans* retinoic acid, 736
alpha-fetoprotein expression, 75
amrubicin, 513
amrubicinol, 513
AN-162, 553
anaplastic large-cell lymphoma, 364
anaplastic lymphoma kinase, 364
angiogenesis, 83, 355
anthracycline, 513
antiangiogenesis, 197
antiangiogenic drugs, 81
anticancer agent, 607
anticancer drug, 676, 815
anticoagulant, 822
antiestrogen-resistant, 51
antimitotics, 469
antineoplastic drugs, 1
antiproliferation, 926
antiproliferative, 543
antitumor, 543
antitumor agent, 425
apoptosis, 33, 41, 59, 83, 131, 141, 249, 267, 321, 355, 373, 382, 416, 425, 573, 601, 646, 659, 668, 676, 702, 713, 757, 770, 787, 815, 880, 910
artemisinin, 910
ASE-1, 174
asparaginase, 1
ATP noncompetitive inhibitors, 364
autophagy, 779
axitinib, 81
Barrett's esophagus, 437
belinostat, 682
berberine, 757
beta-blocker, 477
beta-carboline alkaloids, 373
beta-lapachone, 901
bevacizumab, 81, 893
Bid, 713
biliary cancer, 294
bioavailability, 584
biological modifiers, 21
biomarkers, 616
bioreductive agents, 493
bioreductive drug, 901
bladder carcinoma, 469
bleomycin, 157
brain, 157
brain metastasis, 301
brain tumors, 794
BRCA1, 634
BRCA2, 634
breast cancer, 51, 115, 217, 334, 503, 553, 607, 634, 723, 946
breast cancer cell lines, 918
breast cancer differentiation, 736
bufalin, 59
caelyx, 918
caffeine, 746
cAMP signaling, 477
camptothecin, 634
cancer, 757
capecitabine, 75, 191, 204, 217
carboplatin, 185, 305
carcinoma, 822
cardiomyopathy, 79
cardiotoxicity, 15, 79, 109
Casitas B-lineage lymphoma proteins, 59
caspase, 425, 815
caspase-3, 249
castration-resistant, 179
castration-resistant prostate cancer, 215
CD3EAP, 174
celecoxib, 294
cell cycle, 230, 469, 534, 659, 880
cell cycle arrest, 416, 926
cell death, 723
cell growth, 267
cell proliferation, 141
cetuximab, 355, 450
chemoprevention, 437
chemoradiotherapy, 519
chemosensitizer, 21
chemotherapy, 79, 105, 115, 204, 281, 389, 396, 403, 770, 932
chemotherapy-induced amenorrhea, 503
childhood, 7
children, 794
chloroquine, 736
chlorpromazine, 723, 746
cholangiocarcinoma, 294
cholecystokinin, 527
chordoma, 953
chronic myeloid leukemia, 573
circulating endothelial cells, 197
cisplatin, 191, 208, 305, 559, 752, 838, 901, 932, 941
c-jun NH₂-terminal kinase, 382
CK2, 238
clinical trial, 157
clonogenic survival, 659
coenzyme Q₀, 33
colon cancer, 355, 601
colorectal cancer, 217, 396, 845, 867
combi-molecule, 659
combination, 115
combination chemotherapy, 312
combination therapy, 41
comet assay, 659
concurrent chemoradiotherapy, 639
conjugates, 676
controlled release, 89
CPT-11, 589
craniopharyngioma, 157
curcumin, 444
cutaneous eruption, 1
cyclodextrin, 822
cyclooxygenase, 294
cytochromes P450, 305
cytotoxic activity, 918
cytotoxic anticancer drug, 312
cytotoxic rosamines, 461
death receptor, 770
delayed diarrhoea, 867
devazepide, 527
diacetyldianhydrogalactitol, 926
diallyl trisulfide, 702
diarylpropenones, 469
differentiation, 573
dihydroartemisinin, 131
DNA methylation, 208
DNA-array, 559
docetaxel, 204, 267, 450, 508, 589, 639, 752, 932, 946
doxorubicin, 238, 382, 553, 607
doxycycline, 115
drug delivery systems, 89, 607
drug discovery, 149
drug interaction, 123
drug metabolism, 867
drug resistance, 932
dynamic contrast-enhanced magnetic resonance imaging, 483
efficacy, 191, 867
Ehrlich ascites tumor, 746
elderly, 105, 281
electrochemotherapy, 157
electroporation, 157
emodin, 238
end stage renal disease, 848
endocrine receptor negative, 197
endothelin 1, 83
endothelin A receptor, 83
enediynes, 41
enzyme, 757
epidermal growth factor receptor, 65, 851, 856, 953
epidermal growth factor receptor tyrosine kinase inhibitors, 659, 953
epidermoid carcinoma, 41
epigallocatechin gallate, 584
epipodophyllotoxins, 1
erlotinib, 856, 953
esophageal adenocarcinoma, 437
esophageal cancer, 89
estramustine, 508
estrogen receptor-negative, 33
estrogen-independent, 51
everolimus, 893
Ewing's tumors, 527
experimental drugs, 880
external-beam radiation, 89
extracellular regulated kinase, 208
extracellularly regulated kinase 1 and 2, 334

- ferrocene, 676
 FFC14A, 97
 flavonoids, 543, 573
 flow cytometry, 230
 fluorouracil, 79, 287
 folate, 607
 FOLFOX, 845
 folinic acid, 822
 FSaII tumor, 901
- gallbladder cancer, 123, 294
 gastric cancer, 59, 141, 208, 752
 gefitinib, 41, 832, 856
 gemcitabine, 123, 838, 932
 gene expression, 932
 gene polymorphism, 867
 gene signature, 682
 gene therapy, 389, 403, 589
 genistein, 713
 glutathione, 559
 glutathione S-transferase π , 382
 glutathione S-transferases, 208
 GMX1777, 346
 GMX1778, 346
- half-life, 553
 harmol, 373
 HCT116, 815
 head and neck cancer, 185, 639
 hepatobiliary cancer, 294
 hepatocellular carcinoma, 389, 403
 hepatoma G2 cells, 779
 HER2-negative, 946
 histone acetylation, 321, 736
 histone deacetylase inhibitor, 682, 815
 homocysteine, 787
 human breast cancer, 65, 230
 human breast epithelium, 230
 human chromosome 19q13.3, 174
 human epidermal growth factor family, 450
 human liver microsomes, 305
 hyaluronan
 oligosaccharides, 800
 hydroxychloroquine, 736
 hypersensitivity reactions, 1
 hypertension, 81
- Illudin M, 676
 imatinib, 953
 induction chemotherapy, 639
 inflammatory breast cancer, 197
 inhibitor, 238
 inhibitors of apoptosis, 646
- interferon- α , 893
 intra-arterial infusion chemotherapy, 941
 intracerebral, 157
 intracystic, 157
 intralesional injection, 89
 intrathecal chemotherapy, 301
 intrathecal liposomal cytarabine, 794
 intratumoral, 157
 invasion, 83
 in-vivo antitumor activity, 364
 ionizing radiation, 659
 irinotecan, 165, 287, 301, 508, 519, 867
 ischaemia, 79
- K562, 815
 K562 cells, 573
 K562/A02 cells, 800
 kidney cancer, 409
 kinase inhibitors, 364
 KP1019, 97
- lapatinib, 918
 laryngeal carcinoma, 807
 leptomeningeal carcinomatosis, 301
 leucovorin, 281
 lidamycin, 41
 lipophilic cations, 461
 liver metastases, 845
 low-dose metronomic chemotherapy, 355
 lung cancer, 513
 lung carcinoma, 41, 373
- magnetic poly (N-isopropylacrylamide) microspheres, 607
 mammalian target of rapamycin, 259
 mammary carcinoma, 334
 MAPK signal pathway, 65
 marine natural products, 425
 MDA-MB-231, 33
 MDM2, 416
 mechanism of action, 149
 mechanistic specificity, 21
 medulloblastoma, 770, 794
 melanoma, 676, 910
 menopausal status, 503
 metal-binding domain, 21
 metastasis, 21, 334
 metastatic, 294, 946
 metastatic breast cancer, 109, 204, 616
 metastatic gastric cancer, 301
 metastatic penile cancer, 277
 methotrexate, 787
- methoxy poly(ethylene glycol)-poly(lactide-co-glycolide), 807
 methylenetetrahydrofolate reductase, 787
 microarray, 51
 microtubule inhibitors, 508
 mitochondria, 425, 779
 mitomycin C, 634, 746, 941
 monoclonal antibody, 851
 mTOR kinase inhibitor, 693
 multidrug resistance, 321
 multidrug resistance protein 2, 559
 multidrug resistance reversal, 382
 multiple myeloma, 259
- N-acetyltransferase human, 668
 nanomedicine, 607
 nanoparticle, 807
 naphthyridines, 493
 natural products, 149
 NCI60, 174
 neurotoxicity, 396
 neutropenia, 867
 NF κ B/p65, 832
 nicotinamide adenine dinucleotide, 346
 nicotinamide phosphoribosyl transferase, 346
 nicotinic acetylcholine receptor, 477
 nitroimidazoles, 493
 NK cells, 910
 non-small cell lung cancer, 105, 838, 932
 NQO1, 901
 nucleophosmin-anaplastic lymphoma kinase, 364
 nutritional status, 625
 NVP-AEW541, 259
- oesophageal cancer, 165
 osteogenesis, 83
 osteosarcoma, 702
 ovarian cancer, 450, 589
 ovarian carcinoma, 267
 oxaliplatin, 75, 105, 123, 281, 287, 305, 396, 845
 oxoplatin, 559
- P21, 534
 p21 (waf1), 832
 P27, 534
 p53, 416, 589
 p53 gene, 389, 403
 paclitaxel, 89, 185, 277, 355, 601, 807
 p-Akt, 832
 palliative chemotherapy, 165
 pancreatic cancer, 131, 149, 444, 634
- pancreatic cancer prevention, 477
 para-toluenesulfonamide, 838
 PCNA, 534
 pegylated liposomal doxorubicin, 15
 peptide therapeutic, 21
 perfusion, 483
 pertuzumab, 450
 P-glycoprotein, 267
 pharmacodynamic marker, 346
 pharmacodynamics, 513
 pharmacokinetics, 7, 89, 97, 312, 396, 584, 856
 pharmacology, 217, 856
 phase I, 97
 phase II trial, 616
 phosphatidylinositol 3 kinase, 259
 PI3K/Akt pathway, 249
 plasma concentration, 513
 platinum-containing compounds, 1
 platinum-DNA adducts, 396
 polyamine analog, 230
 polymers, 89
 polymorphism, 787
 polyphenols, 543
 prediction, 519
 predictive factors, 851
 prenyl diphosphate synthase, 141
 preoperative chemotherapy, 752
 preterminal cancer, 625
 procarbazine, 1
 proliferation, 83, 131, 573, 757
 prostate cancer, 179
 prostate-specific antigen response, 215
 protein kinases, 238
 proteinuria, 81
 proteome, 702
 proteomic analysis, 668
- QGY-7703, 926
 quinazolines, 493
- racial variability, 867
 Rad001, 259
 randomized clinical trials, 217
 rapamycin, 693
 rats, 483, 584
 reactive oxygen species, 770
 rectal cancer, 519
 redox enzymes, 559
 reduced glutathione, 396
 refractory/recurrent gastric cancer, 191
 relapse, 794
 renal cell carcinoma, 848, 893

- renal toxicity, 81
- resistance, 559
- resorufin, 238
- respiratory arrest, 1
- resveratrol, 437
- reversal effects, 800
- rhein lysinate, 65
- ruthenium, 97

- S-1, 752
- schedule dependence, 123
- second-generation histone deacetylase inhibitors, 321
- second-line chemotherapy, 185
- severe liver dysfunction, 845
- signal transducer and activator of transcription 3, 444
- single nucleotide polymorphisms, 174
- sister chromatid exchanges, 746
- SKBr3, 33

- Smac/direct IAP binding protein with low pI, 646
- small molecule tyrosine kinase inhibitor, 851
- SN-38, 267, 589
- soft tissue sarcomas, 15
- somatostatin, 553
- sorafenib, 81, 409, 616, 893
- squamous cell carcinoma, 668
- Src inhibitor, 179
- structure–activity relationship, 573
- subunit 2, 141
- sunitinib, 81, 848, 893
- survival, 625
- survivin, 249, 646
- synergy, 312
- systemic disease, 21

- T cells, 910
- tamoxifen, 584
- tamoxifen resistance, 723
- targeted therapies, 553, 893
- taxanes, 1

- thioguanine, 7
- thrombospondin-1, 355
- thymidine phosphorylase, 217
- thymidylate synthase, 519
- topoisomerase I, 519, 634
- topoisomerase I inhibitor, 634
- topoisomerase II inhibitor, 513
- toxicity, 191, 867
- TRAIL, 646, 713
- tranilast, 334
- transcatheter arterial chemoembolization, 389, 403
- transforming growth factor-beta, 334
- transgenic mouse model, 910
- transplatin, 305
- transplatin derivatives, 305
- trastuzumab, 109, 450
- triterpenoids, 880
- tryptanthrin, 382

- tumor, 483
- tumor necrosis factor- α , 832
- tumor suppress, 141
- tyrosinleutide (YSL), 534

- UGT1A1, 867
- unfolded protein response, 601
- unresectable, 294
- ursolic acid, 249

- vascular-disrupting agent, 483
- vinorelbine, 105, 932
- vorinostat, 321

- weekly, 109
- Wnt, 543

- xenograft, 65
- xenograft model, 932
- X-linked inhibitor of apoptosis, 646

- ZD4054, 83